LYZ and cancer: In particular, the DSS-TAS active component shared only three genes with both the GE (HOXA1, GPRC5A and LYZ) and CN (ABL1, ABL2 and CTNNB1) and none with the mutational profiles; although this surprisingly small overlap may be attributed in part to the rather sparse mutation panel, it also demonstrates that the functional drug/target profiling provides added value to the genomics-only-based analyses and that the targets deemed functionally critical by the addiction scoring are not necessarily overlapping with those detected by genomic analyses of the same cancer cells.